METHOD OF LYMPH THERAPY EFFICIENCY FORECAST Russian patent published in 2009 - IPC A61B10/00 G01N33/52 

FIELD: medicine.

SUBSTANCE: invention concerns medicine, particularly oncology and hematology, and biochemistry. Method of lymph therapy efficiency forecast involves the following. Cysteine protease activity of B and L cathepsin lysosomes is measured in patient's blood serum before treatment. Sensitivity or specificity level is defined for the method. Cathepsin B and cathepsin L dispersal points related to the defined sensitivity or specificity level are determined by diagram of sensitivity and specificity dependency on cathepsin B and L activity, e.g. by diagrams in Fig. 1 and 2. If cathepsin B and L activity for a patient is above activity of respective enzyme in dispersion point, then high treatment efficiency for this patient is forecast; and if cathepsin B and L activity for a patient is equal to or below activity of respective enzyme in dispersion point, then low treatment efficiency for this patient is forecast If activity of one enzyme for patient is above its activity in dispersion point while activity of the other enzyme is equal to or below its activity in dispersion point, then degree of activity deviation from dispersion point is defined for each enzyme by relative deviation value calculation. It involves division of absolute difference value between enzyme activity in dispersion point and on patient's diagram on activity value for the same enzyme in dispersion point. If relative deviation is higher for the enzyme with activity above its activity in dispersion point then high treatment efficiency for this patient is forecast; and if relative deviation is higher for the enzyme with activity below its activity in dispersion point then low treatment efficiency for this patient is forecast Sensitivity and specificity level of method and dispersion points can attain the following values for non-Hodgkin lymphoma: sensitivity of 79%, specificity of 62%, cathepsin B activity 2.6 nmol MCA/min per l, cathepsin L activity 17.0 nmol MCA/min per l; for Hodgkin disease: sensitivity of 89%, specificity of 69%, cathepsin B activity 3.1 nmol MCA/min per l, cathepsin L activity 22.5 nmol MCA/min per l; additionally: sensitivity of 78%, specificity of 85%, cathepsin B activity 2.8 nmol MCA/min per l, cathepsin L activity 21.0 nmol MCA/min per l; cathepsin B activity 2.9 nmol MCA/min per l, cathepsin L activity 21.5 nmol MCA/min per l.

EFFECT: high accuracy due to account of tumour progression mechanism.

4 cl, 4 tbl, 2 dwg,10 ex